Developing next generation treatments to preserve vision for patients with diseases affecting the back of the eye

Latest news

Read or download our press releases for all latest news about our company, research & development activities and updates for investors. Consult our event calendar for an overview of conferences or meetings where you will be able to meet up with Oxurion associates. Be sure to check in regularly for the latest Oxurion press releases or just subscribe to our mailing list to receive regular updates.

Subscribe to our mailing list

9 Sep 2021
Company; THR-149; THR-687; Investors
Oxurion NV Business & Financial Update – H1 2021

Highlights

...

8 Sep 2021
THR-149; own; thr-687
OXURION to Present Clinical and Pre-Clinical Data at Upcoming EURETINA 2021 Virtual Congress

Leuven, BE, Boston, MA, US – September 8  – 08.00 AM CET   ...

17 Aug 2021
THR-687; own
Oxurion NV - Publication of Positive Phase 1 Clinical Data evaluating THR-687 for Treatment of DME in Ophthalmology Science, the American Academy of Ophthalmology Journal

Leuven, BE, Boston, MA, US – August 17, 2021 – 08.00 AM CET –...

16 Aug 2021
Oxurion NV - Journal of Pharmacokinetics and Pharmacodynamics highlights desirable PK/PD profiles of THR-687 and THR-149

Leuven, BE, Boston, MA, US – August 16, 2021 – 8.00 AM CET – Oxurion NV (...

5 Aug 2021
Company; THR-149; THR-687; Investors
OXURION to Participate in Upcoming Investor Meetings

Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical...

25 Jun 2021
Company; THR-149; THR-687; Investors
Oxurion NV to Focus Resources on Clinical Assets THR-687 and THR-149

Leuven, BE, Boston, MA, US – June 25, 2021 – 07.00 AM CET – ...

10 Jun 2021
Company; THR-687
OXURION Confirms Institutional Review Board Approval and Submission of the Investigational New Drug Application to the FDA to Start Phase 2 Study Evaluating THR-687 for Diabetic Macular Edema (DME)

Leuven, BE, Boston, MA, US – June 10, 2021 – 07.00 AM CET –...

Archive

Media contact

Oxurion is committed and engaged to communicate openly with all of its stakeholders. For any media enquiries, comments or questions about Oxurion, please contact our Investor Relations & Corporate Communications team:

Wouter Piepers
Global Head of Corporate Communications and Investor Relations

Gaston Geenslaan 1
B-3001 Heverlee
Belgium
Tel: +32 16 751 310
Cell: +32 478 33 56 32
wouter.piepers@oxurion.com